| abstract |
The present invention relates to an immune checkpoint inhibitor pharmaceutical composition containing a porcine potato extract or 3-Hydroxy-8β-tigloyloxy-1,10-dehydroariglovin compound isolated therefrom as an active ingredient, and anti-programmed cell death-1 (Programmed Cell death protein 1; PD-1) and anti-programmed death-ligand 1 (PD-L1) interfere with the interaction and proliferate the activity of T cells. Provides a pharmaceutical composition for the treatment of immune checkpoint inhibitors that attack transformed tissues, etc., and that can help enhance immunity. |